2 days ago
Forbes Sep 18, 2026

Erin Andrews Talks About Lessons From Her Cervical Cancer Journey

Erin Andrews, known for her role as a sideline reporter for ESPN and FOX Sports, faced a life-altering moment in September 2016 when a routine gynecological exam revealed she had cervical cancer. At 38, Andrews, with no prior symptoms, learned that the cancer was in an early stage, which allowed for surgical intervention. After multiple surgeries to fully remove the cancer, she avoided radiation therapy, but the diagnosis profoundly impacted her perspective on health.

Initially, Andrews kept her diagnosis private at work, hesitant to discuss something as personal as cervical cancer in a male-dominated sports environment. However, after revealing her journey in an interview, her openness struck a chord, leading to widespread support from colleagues and even NFL figures like New England Patriots owner Robert Kraft. She now maintains regular yearly check-ups to monitor her health, emphasizing the importance of vigilance even after treatment.

The experience changed Andrews' attitude toward medical screenings and doctor visits, which now bring anxiety due to the fear of recurrence. She shared how a worrisome mammogram disrupted her focus during a major event like the Super Bowl, illustrating the emotional toll that cancer survivors often carry. Despite these challenges, she uses her story to encourage others to prioritize early cancer detection, highlighting established screenings for cancers like cervical, breast, prostate, colorectal, and lung.

Motivated by her journey, Andrews has become a vocal advocate for cancer screening and early detection. She partners with Exact Sciences to promote Cancerguard, a blood test that screens for biomarkers linked to over 50 cancer types, including those without routine screening methods. While career pursuits continue robustly, with projects like her podcast and game show hosting, Andrews now balances professional success with a renewed focus on personal health and mental wellness.

0
0 Read source
Share this post
Facebook Twitter LinkedIn

Discussion

0 comments

No comments yet

Start the discussion with a take, question, or market read.